Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.4337
+0.0137 (3.26%)
Jan 2, 2026, 3:58 PM EST - Market open
Sangamo Therapeutics Employees
Sangamo Therapeutics had 183 employees as of December 31, 2024. The number of employees decreased by 222 or -54.81% compared to the previous year.
Employees
183
Change (1Y)
-222
Growth (1Y)
-54.81%
Revenue / Employee
$179,645
Profits / Employee
-$595,131
Market Cap
145.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 183 | -222 | -54.81% |
| Dec 31, 2023 | 405 | -73 | -15.27% |
| Dec 31, 2022 | 478 | 47 | 10.90% |
| Dec 31, 2021 | 431 | 18 | 4.36% |
| Dec 31, 2020 | 413 | 59 | 16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SGMO News
- 15 days ago - Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - GlobeNewsWire
- 4 weeks ago - Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - GlobeNewsWire
- 6 weeks ago - Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease - GlobeNewsWire
- 2 months ago - Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call - GlobeNewsWire
- 4 months ago - Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 - GlobeNewsWire
- 5 months ago - Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript - Seeking Alpha